^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced non-squamous NSCLC previously treated with chemotherapy

Published date:
12/15/2020
Excerpt:
...105 chemotherapy-pretreated patients with non-squamous NSCLC were enrolled and received apatinib 250 mg (recommended phase 2 dose) and camrelizumab….Efficacy of combination therapy was evident across all PD-L1 and tumor mutation burden subgroups, and appeared to be improved in patients with STK11/KEAP1 mutation (mutant vs . wild-type, ORR: 42.9% vs 28.1%; 1-year survival rate: 85.1% vs. 53.1%).
DOI:
10.1158/1078-0432.CCR-20-3136